Hinova Pharmaceuticals, Inc. Class ASSE: 688302

Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical Trial Application for HP515 Tablets to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)

· Issued by Hinova Pharmaceuticals, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Obtaining FDA Approval for Clinical Trial Application for HP515 Tablets to Treat Metabolic Dysfunction-Associated Steatohepatitis (MASH)

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment